SEC Form 4 · accession 0001179110-15-001133

ACCELERON PHARMA INC · XLRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Matthew L Sherman

Officer — SVP & Chief Medical Officer

Period of report

Jan 20, 2015

Accepted (ET)

Jan 22, 2015 · 4:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001280600

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 20, 2015	M	1,600	$5.08	A	21,604	D
Common Stock^F2	Jan 20, 2015	S	1,600	$41.78	D	20,004	D
Common Stock	Jan 20, 2015	M	4,000	$0.48	A	24,004	D
Common Stock^F3	Jan 20, 2015	S	1,514	$41.23	D	22,490	D
Common Stock^F4	Jan 20, 2015	S	2,486	$41.81	D	24,004	D
Common Stock^F5	Jan 20, 2015	S	400	$41.70	D	20,100	I	By GRAT
Common Stock^F6	Jan 20, 2015	S	1,000	$41.60	D	19,100	I	By GRAT

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F7	$5.08	Jan 20, 2015	M	1,600	D	—	Mar 27, 2018	Common Stock	1,600	27,896	D
Option to Purchase Common Stock^F8	$0.48	Jan 20, 2015	M	4,000	D	—	May 31, 2016	Common Stock	4,000	28,000	D

Explanation of responses

F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.47 to $41.82, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.62 to $41.58, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $42.18, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.33 to $41.82, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.11 to $41.92, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
F7The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
F8The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.